Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors

被引：0
|
作者：
Yanrong Su
Nathan R. Hopfinger
Theresa D. Nguyen
Thomas J. Pogash
Julia Santucci-Pereira
Jose Russo
机构：
[1] Fox Chase Cancer Center-Temple University Health System,The Irma H. Russo, MD Breast Cancer Research Laboratory
来源：
Journal of Experimental & Clinical Cancer Research | / 37卷
关键词：
Triple negative breast cancer; Epithelial mesenchymal transition; DNA methyltransferase; Histone deacetylase;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
    Su, Yanrong
    Hopfinger, Nathan R.
    Nguyen, Theresa D.
    Pogash, Thomas J.
    Santucci-Pereira, Julia
    Russo, Jose
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [2] Epigenetic reprogramming of epithelial-mesenchymal transition in triple-negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
    Su, Yanrong
    Hopfinger, Nathan R.
    Pogash, Thomas J.
    Nguyen, Theresa D.
    Santucci-Pereira, Julia
    Russo, Jose
    CANCER RESEARCH, 2014, 74 (19)
  • [3] The response of histone deacetylase inhibitors in triple negative breast cancer
    Alzoubi, Madlin
    Nguyen, Khoa
    Burks, Hope
    Hebert, Katherine
    Cheng, Thomas
    Matossian, Margarite
    Wright, Maryl
    Collins-Burow, Bridgette
    Burow, Matthew
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Targeting triple negative breast cancer with histone deacetylase inhibitors
    Fedele, Palma
    Orlando, Laura
    Cinieri, Saverio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1199 - 1206
  • [5] Epigenetic reprogramming in cloned mouse embryos following treatment with DNA methyltransferase and histone deacetylase inhibitors
    Zarei, Maryam
    Shamaghdari, Boshra
    Vahabi, Zeinab
    Dalman, Azam
    Eftekhari Yazdi, Poopak
    SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2022, 68 (03) : 227 - 238
  • [6] Reprogramming epithelial-mesenchymal transition and the immune microenvironment in triple-negative breast cancer with epigenetic drugs.
    Yuan, Xueying
    Soth, Michael
    Jones, Philip
    Rosen, Jeffrey
    CANCER RESEARCH, 2022, 82 (23)
  • [7] Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
    Kong, Dejuan
    Ahmad, Aamir
    Bao, Bin
    Li, Yiwei
    Banerjee, Sanjeev
    Sarkar, Fazlul H.
    PLOS ONE, 2012, 7 (09):
  • [8] Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors
    Teixeira, S. R.
    Abreu, C. M.
    Parkes, L.
    Davies, J.
    Yao, S.
    Sawhney, M. A.
    Margarit, L.
    Gonzalez, D.
    Mendes Pinto, I.
    Francis, L. W.
    Conlan, R. S.
    BIOSENSORS & BIOELECTRONICS, 2019, 141
  • [9] Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer
    Liu, Yajing
    Martin-Trevino, Rachel
    Shang, Li
    Davis, April
    Wicha, Max
    Liu, Suling
    Burness, Monika
    CANCER RESEARCH, 2015, 75
  • [10] Epigenetic therapy in cancer: Molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors
    Schneider-Stock, Regine
    Ocker, Matthias
    IDRUGS, 2007, 10 (08) : 557 - 561
12345